Your browser is no longer supported. Please, upgrade your browser.
ARDS Aridis Pharmaceuticals, Inc. daily Stock Chart
Aridis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.68 Insider Own45.04% Shs Outstand8.54M Perf Week-24.60%
Market Cap73.27M Forward P/E- EPS next Y-3.20 Insider Trans- Shs Float5.99M Perf Month2.45%
Income-29.80M PEG- EPS next Q-0.39 Inst Own0.60% Short Float0.12% Perf Quarter0.94%
Sales3.40M P/S21.55 EPS this Y16.80% Inst Trans-16.33% Short Ratio0.71 Perf Half Y-1.38%
Book/sh1.34 P/B6.40 EPS next Y2.10% ROA-109.00% Target Price21.75 Perf Year-35.00%
Cash/sh1.00 P/C8.62 EPS next 5Y- ROE-136.60% 52W Range6.91 - 13.38 Perf YTD-22.63%
Dividend- P/FCF- EPS past 5Y- ROI-91.70% 52W High-35.87% Beta-
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low24.08% ATR1.08
Employees23 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)42.25 Volatility13.67% 11.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-327.70% Profit Margin- Rel Volume0.64 Prev Close8.23
ShortableYes LT Debt/Eq0.00 EarningsAug 13 Payout- Avg Volume10.26K Price8.58
Recom- SMA20-12.78% SMA50-10.63% SMA200-10.72% Volume6,569 Change4.25%
Sep-08-19 04:28PM  Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019 PR Newswire
Sep-03-19 09:18AM  Aridis Pharmaceuticals stock plunges after drug trial fails to meet primary endpoint MarketWatch -6.64%
05:30AM  Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa PR Newswire
Aug-14-19 03:40PM  Its not just Bloom Energy: Half of last years Bay Area IPO stocks are underwater American City Business Journals
Aug-12-19 04:05PM  Aridis Pharmaceuticals Announces Second Quarter 2019 Results PR Newswire
Jul-31-19 03:01PM  Do Insiders Own Lots Of Shares In Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS)? Simply Wall St. -13.95%
Jul-30-19 05:30AM  Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology PR Newswire +5.97%
Jul-19-19 05:30AM  Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501 PR Newswire
Jun-27-19 05:30AM  Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501 PR Newswire
Jun-10-19 05:30AM  Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors PR Newswire -6.42%
May-14-19 04:35PM  Aridis Pharmaceuticals Announces First Quarter 2019 Results PR Newswire
Apr-03-19 07:21AM  Will Aridis Pharmaceuticals Continue to Surge Higher? Zacks
Apr-02-19 09:00AM  Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why Zacks
Mar-28-19 04:05PM  Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire -8.89%
Jan-31-19 10:40AM  Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals Simply Wall St. -8.65%
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals -5.32%
Dec-12-18 07:30AM  AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients PR Newswire +15.10%
Dec-05-18 10:35AM  This year's Bay Area IPO batch remains up 44% despite market turbulence American City Business Journals
Dec-04-18 12:30PM  Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations PR Newswire -14.57%
Nov-26-18 10:04AM  Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics American City Business Journals
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-13-18 07:30AM  Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview PR Newswire
Nov-07-18 07:30AM  Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine" PR Newswire +7.36%
Sep-26-18 08:30AM  Aridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-24-18 07:00AM  Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates PR Newswire +7.99%
Aug-13-18 07:31PM  Aridis Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.